Spyre Therapeutics
SYRE
68 hedge funds and large institutions have $158M invested in Spyre Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
2% more capital invested
Capital invested by funds: $154M → $158M (+$3.44M)
0.07% more ownership
Funds ownership: 2.78% → 2.85% (+0.07%)
4% less funds holding
Funds holding: 71 → 68 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$785K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$445K |
| 3 |
SCA
Snowden Capital Advisors
New York
|
+$403K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$400K |
| 5 |
Two Sigma Investments
New York
|
+$390K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.85M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$385K |
| 3 |
DAM
Deltec Asset Management
New York
|
-$192K |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$180K |
| 5 |
Squarepoint
New York
|
-$178K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
ProShare Advisors
Bethesda,
Maryland
| – | -$83K | -432 | Closed |
|
77
AQR Capital Management
Greenwich,
Connecticut
| – | -$82K | -428 | Closed |
|
|
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$78.9K | -411 | Closed |
|
|
ARTA
79
A.R.T. Advisors
New York
| – | -$78K | -405 | Closed |
|
80
Victory Capital Management
San Antonio,
Texas
| – | -$36K | -189 | Closed |
|
SYRE Hedge Fund Activity: Q4 2019 in Review
68 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2019, worth a combined $158M — up 2.2% from $154M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SYRE and 9 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 20 added.
The largest buyer was P.A.W. Capital, opening a new position worth an estimated $785K. The largest seller was Deerfield Management, exiting entirely with an estimated $3.85M sold.
- 68 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2019, down from 71 in Q3 2019.
- Funds reported $158M of Spyre Therapeutics stock for Q4 2019, up 2.2% quarter-over-quarter.
- 9 funds opened new Spyre Therapeutics positions in Q4 2019 and 12 closed out, a net change of -3 holders.
- The largest Spyre Therapeutics buyer in Q4 2019 was P.A.W. Capital, an estimated $785K added.
- The largest Spyre Therapeutics seller in Q4 2019 was Deerfield Management, an estimated $3.85M sold.
Based on aggregated 13F filings for Q4 2019.